Toby M. Maher

33.9k total citations · 12 hit papers
437 papers, 15.6k citations indexed

About

Toby M. Maher is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Pathology and Forensic Medicine. According to data from OpenAlex, Toby M. Maher has authored 437 papers receiving a total of 15.6k indexed citations (citations by other indexed papers that have themselves been cited), including 386 papers in Pulmonary and Respiratory Medicine, 95 papers in Physiology and 73 papers in Pathology and Forensic Medicine. Recurrent topics in Toby M. Maher's work include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (357 papers), Sarcoidosis and Beryllium Toxicity Research (77 papers) and Systemic Sclerosis and Related Diseases (72 papers). Toby M. Maher is often cited by papers focused on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (357 papers), Sarcoidosis and Beryllium Toxicity Research (77 papers) and Systemic Sclerosis and Related Diseases (72 papers). Toby M. Maher collaborates with scholars based in United Kingdom, United States and Germany. Toby M. Maher's co-authors include Athol U. Wells, Elisabetta Renzoni, Philip L. Molyneaux, Michael Kreuter, Paolo Spagnolo, David M. Hansell, Marlies Wijsenbeek, Andrew G. Nicholson, Vincent Cottin and Susanne Stowasser and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Toby M. Maher

398 papers receiving 15.4k citations

Hit Papers

Nintedanib for Systemic Sclerosi... 2008 2026 2014 2020 2019 2008 2020 2019 2014 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease
    2019 956 citations Martina Gahlemann, Arata Azuma et al. New England Journal of Medicine profile →
  2. Interstitial Lung Disease in Systemic Sclerosis
    2008 815 citations Nicole Goh, Sujal R. Desai et al. American Journal of Respiratory and Critical Care Medicine profile →
  3. Idiopathic pulmonary fibrosis: Disease mechanisms and drug development
    2020 392 citations Toby M. Maher et al. profile →
  4. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial
    2019 391 citations Toby M. Maher, Tamera J. Corte et al. profile →
  5. The Role of Bacteria in the Pathogenesis and Progression of Idiopathic Pulmonary Fibrosis
    2014 372 citations Philip L. Molyneaux, Michael J. Cox et al. American Journal of Respiratory and Critical Care Medicine profile →
  6. Global incidence and prevalence of idiopathic pulmonary fibrosis
    2021 344 citations Toby M. Maher, Michael Kreuter et al. Respiratory Research profile →
  7. Interstitial lung diseases
    2022 246 citations Marlies Wijsenbeek, Toby M. Maher et al. profile →
  8. Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis
    2022 139 citations Luca Richeldi, Arata Azuma et al. New England Journal of Medicine profile →
  9. Interstitial Lung Disease
    2024 111 citations Toby M. Maher JAMA profile →
  10. Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis
    2025 28 citations Luca Richeldi, Arata Azuma et al. New England Journal of Medicine profile →
  11. Nerandomilast in Patients with Progressive Pulmonary Fibrosis
    2025 19 citations Toby M. Maher, Arata Azuma et al. New England Journal of Medicine profile →
  12. Fibrosis: cross-organ biology and pathways to development of innovative drugs
    2025 15 citations Toby M. Maher et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Toby M. Maher United Kingdom 63 12.7k 3.8k 3.4k 2.4k 1.9k 437 15.6k
Kevin K. Brown United States 70 12.2k 1.0× 4.8k 1.3× 2.3k 0.7× 2.5k 1.0× 1.4k 0.7× 203 15.3k
Vincent Cottin France 72 16.2k 1.3× 5.0k 1.3× 2.9k 0.9× 3.3k 1.3× 1.3k 0.7× 524 19.4k
Roland M. du Bois United Kingdom 69 16.2k 1.3× 6.2k 1.6× 4.1k 1.2× 3.2k 1.3× 1.8k 1.0× 143 19.5k
Luca Richeldi Italy 65 13.1k 1.0× 4.8k 1.3× 1.7k 0.5× 3.9k 1.6× 1.7k 0.9× 356 18.3k
Martin Kolb Canada 62 10.6k 0.8× 2.8k 0.7× 1.2k 0.4× 1.3k 0.5× 2.7k 1.4× 279 14.9k
Kevin R. Flaherty United States 55 9.1k 0.7× 3.0k 0.8× 1.1k 0.3× 1.2k 0.5× 1.1k 0.6× 196 10.9k
Ganesh Raghu United States 81 22.0k 1.7× 7.6k 2.0× 2.8k 0.8× 3.6k 1.5× 2.2k 1.1× 332 26.7k
Demosthenes Bouros Greece 58 8.5k 0.7× 2.9k 0.8× 1.1k 0.3× 1.7k 0.7× 1.6k 0.8× 377 11.9k
Bruno Crestani France 58 6.7k 0.5× 2.1k 0.6× 997 0.3× 1.3k 0.5× 2.1k 1.1× 359 10.7k
Dominique Valeyre France 66 13.1k 1.0× 8.4k 2.2× 1.1k 0.3× 2.7k 1.1× 1.8k 0.9× 401 18.8k

Countries citing papers authored by Toby M. Maher

Since Specialization
Citations

This map shows the geographic impact of Toby M. Maher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Toby M. Maher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Toby M. Maher more than expected).

Fields of papers citing papers by Toby M. Maher

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Toby M. Maher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Toby M. Maher. The network helps show where Toby M. Maher may publish in the future.

Co-authorship network of co-authors of Toby M. Maher

This figure shows the co-authorship network connecting the top 25 collaborators of Toby M. Maher. A scholar is included among the top collaborators of Toby M. Maher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Toby M. Maher. Toby M. Maher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Richeldi, Luca, Arata Azuma, Vincent Cottin, et al.. (2025). Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis. New England Journal of Medicine. 392(22). 2193–2202. 28 indexed citations breakdown →
2.
Maher, Toby M., Gísli Jenkins, Vincent Cottin, et al.. (2024). Circulating biomarkers and progression of idiopathic pulmonary fibrosis: data from the INMARK trial. ERJ Open Research. 10(4). 335–2023. 3 indexed citations
3.
Maher, Toby M.. (2024). Interstitial Lung Disease. JAMA. 331(19). 1655–1655. 111 indexed citations breakdown →
4.
Maher, Toby M., Kevin K. Brown, Steve Cunningham, et al.. (2024). Estimating the effect of nintedanib on forced vital capacity in children and adolescents with fibrosing interstitial lung disease using a Bayesian dynamic borrowing approach. Pediatric Pulmonology. 59(4). 1038–1046. 3 indexed citations
5.
Denton, Christopher P., Robert Spiera, David J. Jörg, et al.. (2023). AB0904 BELIMUMAB FOR THE TREATMENT OF INTERSTITIAL LUNG DISEASE ASSOCIATED WITH SYSTEMIC SCLEROSIS: A PHASE 2/3, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL. Annals of the Rheumatic Diseases. 82. 1668–1668. 1 indexed citations
6.
Hewitt, Richard, Franz Puttur, David C. A. Gaboriau, et al.. (2023). Lung extracellular matrix modulates KRT5+ basal cell activity in pulmonary fibrosis. Nature Communications. 14(1). 6039–6039. 27 indexed citations
7.
Sun, Jiehuan, Tong Zhang, Bing Xu, et al.. (2021). 50-gene risk profiles in peripheral blood predict COVID-19 outcomes: A retrospective, multicenter cohort study. EBioMedicine. 69. 103439–103439. 15 indexed citations
8.
Maher, Toby M. & Mary E. Strek. (2019). Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat. Respiratory Research. 20(1). 205–205. 169 indexed citations
9.
10.
Barratt, Shaney, Caroline Jarrett, Khadija Ourradi, et al.. (2017). Differential Expression of VEGF-Axxx Isoforms Is Critical for Development of Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine. 196(4). 479–493. 66 indexed citations
11.
Molyneaux, Philip L., Saffron A.G. Willis‐Owen, Michael J. Cox, et al.. (2017). Host–Microbial Interactions in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine. 195(12). 1640–1650. 142 indexed citations
12.
Russell, Anne‐Marie, Huzaifa Adamali, Philip L. Molyneaux, et al.. (2016). Daily Home Spirometry: An Effective Tool for Detecting Progression in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine. 194(8). 989–997. 114 indexed citations
13.
Piper, Amanda J., Yuanlin Song, Neil D. Eves, & Toby M. Maher. (2014). Year in review 2013: Acute lung injury, interstitial lung diseases, sleep and physiology. Respirology. 19(3). 428–437. 8 indexed citations
14.
Molyneaux, Philip L., Michael J. Cox, Saffron A.G. Willis‐Owen, et al.. (2014). The Role of Bacteria in the Pathogenesis and Progression of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine. 190(8). 906–913. 372 indexed citations breakdown →
15.
Corte, Tamera J., Gregory J. Keir, Konstantinos Dimopoulos, et al.. (2014). Bosentan in Pulmonary Hypertension Associated with Fibrotic Idiopathic Interstitial Pneumonia. American Journal of Respiratory and Critical Care Medicine. 190(2). 208–217. 153 indexed citations
16.
Win, Thida, Benjamin A. Thomas, Tryphon Lambrou, et al.. (2013). Areas of normal pulmonary parenchyma on HRCT exhibit increased FDG PET signal in IPF patients. European Journal of Nuclear Medicine and Molecular Imaging. 41(2). 337–342. 60 indexed citations
17.
Eves, Neil D., Yuanlin Song, Amanda J. Piper, & Toby M. Maher. (2013). Year in review 2012: Acute lung injury, interstitial lung diseases, sleep and physiology. Respirology. 18(3). 555–564. 7 indexed citations
18.
Russell, Anne‐Marie, Philip L. Molyneaux, Athol U. Wells, et al.. (2013). Quality of life measures in patients with idiopathic pulmonary fibrosis. European Respiratory Journal. 42(Suppl 57). P3368–P3368. 2 indexed citations
19.
Maher, Toby M., Iona Evans, Stephen E. Bottoms, et al.. (2010). Diminished Prostaglandin E2 Contributes to the Apoptosis Paradox in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine. 182(1). 73–82. 153 indexed citations
20.
Goh, Nicole, Sujal R. Desai, Srihari Veeraraghavan, et al.. (2008). Interstitial Lung Disease in Systemic Sclerosis. American Journal of Respiratory and Critical Care Medicine. 177(11). 1248–1254. 815 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kevin K. Brown Breakdown of academic impact, for papers by Vincent Cottin Breakdown of academic impact, for papers by Roland M. du Bois Breakdown of academic impact, for papers by Luca Richeldi Breakdown of academic impact, for papers by Martin Kolb Breakdown of academic impact, for papers by Kevin R. Flaherty Breakdown of academic impact, for papers by Ganesh Raghu Breakdown of academic impact, for papers by Demosthenes Bouros Breakdown of academic impact, for papers by Bruno Crestani Breakdown of academic impact, for papers by Dominique Valeyre
Rankless by CCL
2026